No Data
No Data
Saisheng Pharmaceutical: 2024 Semi-Annual Report
Saisheng Pharmaceutical: 2024 Semi-Annual Report Summary
Beijing Science Sun Pharmaceutical (300485.SZ): The net loss in the first half of the year was 105 million yuan, turning into a loss year-on-year.
Beijing Science Sun Pharmaceutical (300485.SZ) released its semi-annual report on August 27th, with revenue of 0.215 billion yuan, a year-on-year decrease of 21.03%, net loss of 0.105 billion yuan, a year-on-year loss, non-GAAP net income of 18.088 million yuan, a year-on-year decrease of 8.11%, and basic EPS of -0.22 yuan.
Beijing Science Sun Pharmaceutical (300485.SZ): The national cancer center/ethics committee of the Beijing Union Medical College of China Medical Science Academy approved the report on the injection of humanized anti-VEGF monoclonal antibodies.
On July 22nd, Gelunhui reported that Beijing Science Sun Pharmaceutical (300485.SZ) has developed a "humanized anti-VEGF monoclonal antibody injection" which has been approved by the Ethics Committee of the National Cancer Center/Beijing Union Medical College Cancer Hospital of China Academy of Medical Sciences. This marks the confirmation of Phase III clinical trial program and the approval for substantial implementation of the trial. Bevacizumab is a humanized anti-VEGF monoclonal antibody that can be widely used as an anti-angiogenic drug for various tumors, by inhibiting the generation of new blood vessels in tumors via blocking VEGF. This can cut off the blood supply to tumor regions, inhibiting the growth and metastasis of tumors.
Beijing Science Sun Pharmaceutical (300485.SZ): Strengthen the development of new drug delivery technologies, increase research and development investment in new products such as peptides and biotransformation technologies.
Beijing Science Sun Pharmaceutical (300485.SZ) stated on the investor interaction platform on July 16th that the company's main products are biochemical pharmaceuticals, involving three major therapeutic areas: cardiovascular and cerebrovascular diseases, immune diseases (anti-tumor), and neurological diseases. The company has always been committed to the research and development, production and sales of biochemical drugs, strengthened the development of new drug delivery technologies, increased investment in the development of new products such as polypeptide and biotransformation technology products, and based on the current product structure and the company's existing resource conditions, carried out in-depth research on polypeptide-based biomedicine, biobased materials, and pre-diagnosis and management of chronic diseases.
Beijing Science Sun Pharmaceutical (300485.SZ): The main products are biopharmaceuticals, involving three major fields of medication for cardiovascular diseases, immune diseases (anti-tumor) and nervous system diseases.
Beijing Science Sun Pharmaceutical (300485.SZ) stated on the investor interaction platform that the company's leading products are biopharmaceutical products involving three major therapeutic areas: cardiovascular and cerebrovascular diseases, immunological diseases (anti-tumor) and neurological diseases. The company is the original drafting unit of national drug standards for five varieties of products, including fibrinolytic enzyme, fibrinolytic enzyme injection, injection fibrinolytic enzyme, thinsetide injection, and deoxyribonucleoside sodium injection; fibrinolytic enzyme injection, thinsetide injection and 100mg injection of thymopeptide are the first drugs to be produced in China; monosialotetrahexosylganglioside sodium injection.
No Data
No Data